Avastin Alarm

Publication
Article
Oncology Nursing NewsFebruary 2011
Volume 5
Issue 1

A meta-analysis of randomized controlled trials revealed treatment-related fatalities were 1.5 times higher for combination treatment with Avastin (bevacizumab) and chemotherapy versus chemotherapy alone

A meta-analysis of randomized controlled trials revealed treatment-related fatalities were 1.5 times higher for combination treatment with Avastin (bevacizumab) and chemotherapy versus chemotherapy alone. The review, which was published in the Journal of the American Medical Association, included 16 trials with 10,217 patients. Overall, treatment-related death occurred in 2.5% of the Avastin population. The authors maintain the potential survival benefits may still outweigh the fatality risk when evaluating treatment options. Avastin is FDA-approved for the treatment of colon, kidney, brain, and lung cancers; however, the agency is in the process of revoking its breast cancer indication.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
4 experts in this video
4 experts in this video
Image of a woman with glasses in front of a blue background
Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
Image of a woman with gray hair on a light blue background
Photo of a man wearing scrubs in front of a blue background